Inspire Will Use Allergy Expertise To Develop Phase III Antihistamine Compound

Inspire acquires the rights to FAES’ bilastine for the treatment or prevention of allergic rhinitis.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet